Wnt/β-catenin-IN-6
Based on 1 Customer Validation
Wnt/β-catenin-IN-6 is an orally active Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun). Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 can induce apoptosis. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research.
For research use only. We do not sell to patients.
- Purity : 98.34%
- Formula: C25H22N4O3
- Molecular Weight:426.47
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
All EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
COX-2 |
EGFR |
GSK-3β |
ERK |
IL-8 |
Akt |
JNK |
In Vitro
Wnt/β-catenin-IN-6 (Compound B10) (72 h), demonstrates potent cytotoxic activity toward human non-small cell lung cancer cell line A549 (IC50 = 1.28 μM), with IC50 values of 3.74, 3.22, 5.68 μM in SKOV3, MDAMB-231, BEAS-2B cells respectively[1].
Wnt/β-catenin-IN-6 (2, 4 μM, 48 h) shows potent antiproliferative effect by suppressing the EGFR/Erk signaling pathway in A549 cells[1].
Wnt/β-catenin-IN-6 (4 μM, 72 h) induces only 10 % apoptotic response, with no significant difference from the control group in A549 cells[1].
Wnt/β-catenin-IN-6 (2, 4 μM, 48 h) inhibits the Wnt/β-catenin signaling pathway in A549 cells via the AKT/GSK-3β/β-catenin axis[1].
Wnt/β-catenin-IN-6 (2, 4 μM, 48 h) downregulates the IL-8 mRNA expression in A549 cells as well as the expression of c-Myc and c-Jun, suggesting the inflammation-suppression effect[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549 cells
-
Concentration:2, 4 μM
-
Incubation Time:48 h
-
Result:Reduced the phosphorylation levels of EGFR and Erk in A549 cells under basal conditions (without exogenous EGF).
Led to a significant decrease in the expression of phosphorylated EGFR in the presence of EGF, while the inhibition of Erk phosphorylation was less pronounced.
-
Cell Line:A549 cells
-
Concentration:2, 4 μM
-
Incubation Time:48 h
-
Result:Reduced significantly COX2 expression in A549 cells.
Led to a significant reduction in p-AKT levels and the p-AKT to AKT ratio.
Decreased the level of p-GSK-3β dramatically, as well as the ratio of p-GSK-3β to GSK-3β, which in turn led to the downregulation of active (non-phosphorylated) β-catenin.
-
Cell Line:A549 cells
-
Concentration:2, 4 μM
-
Incubation Time:48 h
-
Result:Downregulated the IL-8 mRNA expression in A549 cells, suggesting the inflammation-suppression effect.
Downregulated the expression of c-Myc and c-Jun.
In Vivo
Wnt/β-catenin-IN-6 (12.5-50 mg/kg, i.g., once) exhibits no observable toxicity in ICR mice at doses up to 50 mg/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:An A549 xenograft model established in male BALB/C nude mice (6 weeks)[1]
-
Dosage:25 mg/kg
-
Administration:intragastric gavage (i.g.) every other day
-
Result:Induced no significant differences in body weight, suggesting good systemic tolerance.
Induced no apparent pathological abnormalities.
Exhibited attenuated tumor growth, showing notably stronger tumor inhibition than Gefitinib.
Triggered a marked reduction in Ki67 expression, indicating effective suppression of tumor cell proliferation.
Revealed no evident histopathological abnormalities.
-
Animal Model:ICR mice (20 males and 20 females, 5-6 weeks)[1]
-
Dosage:12.5, 25, 50 mg/kg
-
Administration:intragastric gavage (i.g.)
-
Result:Induced no significant body weight loss.
Induced no apparent pathological abnormalities.
Chemical Information
-
Appearance Solid
-
Molecular Weight 426.47
-
Formula C25H22N4O3
-
Color Light yellow to yellow
-
SMILES
COC1=C(OCC2=CC=CC=C2)C=C(N=CN=C3NC4=CC=C(NC(C=C)=O)C=C4)C3=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 5.83 mg/mL (13.67 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3448 mL | 11.7242 mL | 23.4483 mL | 58.6208 mL |
| 5 mM | 0.4690 mL | 2.3448 mL | 4.6897 mL | 11.7242 mL | |
| 10 mM | 0.2345 mL | 1.1724 mL | 2.3448 mL | 5.8621 mL |